

Edgar Filing: GERON CORP - Form 8-K

GERON CORP
Form 8-K
February 12, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 12, 2007

GERON CORPORATION
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-20859 (Commission File Number)	75-2287752 (IRS Employer Identification No.)
---------------------------------------------------------------	-------------------------------------	----------------------------------------------------

230 CONSTITUTION DRIVE
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices, including zip code)

(650) 473-7700
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On February 12, 2007, Geron Corporation (the "Company") presented an update of its product development programs at the BIO CEO & Investor Conference in New York City.

At this presentation, the Company announced its current plans regarding the clinical development of its telomerase cancer vaccine, GRNVAC1. The Company filed an Investigational New Drug ("IND") application with the Food and Drug

Edgar Filing: GERON CORP - Form 8-K

Agency ("FDA") in November 2006. The Company has received clearance from the FDA and plans to proceed with Phase I clinical trials of GRNVAC1 for patients with acute myelogenous leukemia. The Company is selecting clinical sites for patient enrollment.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: February 12, 2007

By: /s/ David L. Greenwood

David L. Greenwood
Executive Vice President and
Chief Financial Officer